Diagnostics News and Research RSS Feed - Diagnostics News and Research

Alzheimer's Association announces new research grants to study potential drug therapies

Alzheimer's Association announces new research grants to study potential drug therapies

Many academic researchers and pharmaceutical companies have identified new Alzheimer's drug therapy candidates, but lack the funding to move them into human testing. At the same time, few funding sources support early-phase clinical drug trials. As a result, too many promising studies stall out early in the discovery process. [More]
Case Western researchers awarded NSF grant to develop new method to reduce risk of Ebola virus

Case Western researchers awarded NSF grant to develop new method to reduce risk of Ebola virus

Health care workers must diagnose and isolate Ebola victims at an early stage to have a chance to save them and prevent the virus from spreading. But the most sensitive and quickest diagnostic test produces a small percentage of false negative results that undermine efforts to control the deadly agent. [More]
First Major Analysis Of Human Protein Atlas Is Published In Science

First Major Analysis Of Human Protein Atlas Is Published In Science

A research article published today in Science presents the first major analysis based on the Human Protein Atlas, including a detailed picture of the proteins that are linked to cancer, the number of proteins present in the bloodstream, and the targets for all approved drugs on the market. [More]
Cypher Genomics, Sequenom sign development agreement for noninvasive prenatal tests

Cypher Genomics, Sequenom sign development agreement for noninvasive prenatal tests

Cypher Genomics, Inc., the leading genome informatics company, and Sequenom, Inc., the leading molecular diagnostics company, today announced a development agreement for next generation noninvasive prenatal tests (NIPT). [More]
Gensignia's research in CT lung cancer screening recognized by ASCO

Gensignia's research in CT lung cancer screening recognized by ASCO

Gensignia scientific co-founders' research has been recognized in Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology published online in the Journal of Clinical Oncology (JCO) on January 20, 2015. [More]
INRS researchers to use new specialized equipment to study environmental equity, male infertility

INRS researchers to use new specialized equipment to study environmental equity, male infertility

With the acquisition of new specialized equipment, INRS researchers Philippe Apparicio, Géraldine Delbès, and Maritza Jaramillo and their teams will be able to advance knowledge and train highly qualified people in the fields of environmental equity, reproductive toxicology, and the treatment of infections. They received a total of over $1 million from the Quebec government and the John R. Evans Leaders Fund of the Canadian Foundation for Innovation. [More]
Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

bioMérieux, a world leader in the field of in vitro diagnostics, and Astute Medical, Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers, today announced that they have signed a global, semi-exclusive agreement regarding the development of a test for the early risk assessment of acute kidney injury (AKI). [More]
CAP, ASCO University and AMP partner to create Molecular Oncology Tumor Board series

CAP, ASCO University and AMP partner to create Molecular Oncology Tumor Board series

The College of American Pathologists, the American Society of Clinical Oncology's ASCO University, and the Association for Molecular Pathology recently announced their partnership in the creation of the Molecular Oncology Tumor Board series, an online and user-driven resource designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. [More]
Microscopic spheres of calcium phosphate linked to AMD development

Microscopic spheres of calcium phosphate linked to AMD development

Microscopic spheres of calcium phosphate have been linked to the development of age-related macular degeneration (AMD), a major cause of blindness, by UCL-led research. [More]
Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances. [More]
UChicago researchers awarded NIH grants to develop novel medications for sleep apnea, asthma

UChicago researchers awarded NIH grants to develop novel medications for sleep apnea, asthma

Two research teams based at the University of Chicago have received prestigious grants from the National Institutes of Health to develop novel medications to treat sleep apnea and asthma. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
Using breath tests to diagnose liver diseases: an interview with Larry Cohen

Using breath tests to diagnose liver diseases: an interview with Larry Cohen

It was back in the 1960s that scientists first started to understand that breath could be used to find out different things about diseases and other factors. I’m sure you’re familiar with alcohol breath testing, which was patented back in the ‘50s and has been used since the ‘60s. [More]
BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A., granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa. [More]
Mobile diagnosis device to help reduce unnecessary antibiotics prescribing

Mobile diagnosis device to help reduce unnecessary antibiotics prescribing

New biosensor-based technology could help to reduce the over-prescribing of antibiotics by giving GPs and other frontline healthcare staff an accurate and fast method of identifying the nature of infectious diseases. [More]
Signostics gets FDA 510k clearance for handheld bladder scanner

Signostics gets FDA 510k clearance for handheld bladder scanner

Medical device company, Signostics, announced today it has clearance from the U.S. Food and Drug Administration to launch the SignosRT Bladder, the company’s new hand-held bladder scanner. [More]

YODA Project announces availability of clinical trial data for medical devices

The Yale University Open Data Access (YODA) Project is announcing the first-ever broad availability of clinical trial data for medical devices and diagnostics by a company. This historic expansion of data sharing is made possible through collaboration with Johnson & Johnson. [More]
Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

Ultraspecific and extensively validated monoclonal antibodies now available from AMSBIO

AMSBIO has announced the availability of ultraspecific and extensively validated monoclonal antibodies under the UltraMAB™ brand. [More]
Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours. [More]
Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies. [More]